Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites (OaSiS)

20 juli 2022 bijgewerkt door: Wake Forest University Health Sciences

Implementation Of Smoking Cessation Services Within NCI NCORP Community Sites With Organized Lung Cancer Screening Programs

Evaluate a multi-faceted training program to improve short-term smoking cessation rates (<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.

Studie Overzicht

Toestand

Voltooid

Gedetailleerde beschrijving

We utilize an effectiveness-implementation hybrid design, employing a cluster, randomized control trial of community-based NCORP sites to study the effectiveness of a multi-faceted intervention to improve smoking cessation among lung cancer screening patients, as well as dissemination and implementation (D&I) science to optimize and accelerate translation of findings into clinical practice. We will: (1) Evaluate a multi-faceted training program to improve short-term smoking cessation rates (1-week post-visit) and sustained abstinence (6 months) among 1,114 enrolled smokers (557 in each trial arm) who present for LDCT lung cancer screening in community-based lung cancer screening practices; (2) Characterize the adoption and adaptation of the evidence-based tobacco cessation strategies in 26 community-based LDCT lung cancer screening programs; and (3) Develop and evaluate an implementation toolkit for integrating evidence-based tobacco cessation strategies in community-based LDCT lung cancer screening programs. Qualitative data will be collected from key informants at participating screening programs during and after intervention implementation. Quantitative survey data (baseline, <14 days, 3 months, and 6 months) and saliva specimens (6 months only) will be collected from smoking patients receiving screening within these programs.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

1094

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Delaware
      • Newark, Delaware, Verenigde Staten, 19713
        • Helen F Graham Cancer Center
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30912
        • Augusta University Medical Center
      • Savannah, Georgia, Verenigde Staten, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu, Hawaii, Verenigde Staten, 96859
        • Tripler Army Medical Center
    • Illinois
      • Mount Vernon, Illinois, Verenigde Staten, 62864
        • Good Samaritan Regional Health Center
      • Urbana, Illinois, Verenigde Staten, 61801
        • Carle Cancer Center
    • Iowa
      • Ames, Iowa, Verenigde Staten, 50010
        • McFarland Clinic PC - Ames
      • Des Moines, Iowa, Verenigde Staten, 50314
        • Mercy Medical Center - Des Moines
    • Louisiana
      • Shreveport, Louisiana, Verenigde Staten, 71103
        • LSU Health Sciences Center at Shreveport
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48106
        • Saint Joseph Mercy Hospital
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Spectrum Health at Butterworth Campus
      • Royal Oak, Michigan, Verenigde Staten, 48073
        • William Beaumont Hospital-Royal Oak
    • Minnesota
      • Waconia, Minnesota, Verenigde Staten, 55387
        • Ridgeview Medical Center
    • Missouri
      • Ballwin, Missouri, Verenigde Staten, 63011
        • Saint Louis Cancer and Breast Institute-Ballwin
      • Bolivar, Missouri, Verenigde Staten, 65613
        • Central Care Cancer Center - Bolivar
      • Branson, Missouri, Verenigde Staten, 65616
        • Cox Cancer Center Branson
      • Joplin, Missouri, Verenigde Staten, 64804
        • Freeman Health System
      • Joplin, Missouri, Verenigde Staten, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Verenigde Staten, 65401
        • Delbert Day Cancer Institute at PCRMC
      • Rolla, Missouri, Verenigde Staten, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Saint Louis, Missouri, Verenigde Staten, 63131
        • Missouri Baptist Medical Center
      • Saint Louis, Missouri, Verenigde Staten, 63141
        • Mercy Hospital Saint Louis
      • Saint Louis, Missouri, Verenigde Staten, 63109
        • Saint Louis Cancer and Breast Institute-South City
      • Springfield, Missouri, Verenigde Staten, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Verenigde Staten, 65804
        • Mercy Hospital Springfield
      • Washington, Missouri, Verenigde Staten, 63090
        • Mercy Hospital Washington
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, Verenigde Staten, 89503
        • Saint Mary's Regional Medical Center
    • New York
      • Bronx, New York, Verenigde Staten, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Winston-Salem, North Carolina, Verenigde Staten, 27103
        • Novant Health Forsyth Medical Center
    • North Dakota
      • Fargo, North Dakota, Verenigde Staten, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Verenigde Staten, 58103
        • Sanford South University Medical Center
    • Ohio
      • Chillicothe, Ohio, Verenigde Staten, 45601
        • Adena Regional Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73120
        • Mercy Hospital Oklahoma City
    • Pennsylvania
      • Danville, Pennsylvania, Verenigde Staten, 17822
        • Geisinger Medical Center
    • South Carolina
      • Boiling Springs, South Carolina, Verenigde Staten, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Clinton, South Carolina, Verenigde Staten, 29325
        • Prisma Health Cancer Institute - Laurens
      • Easley, South Carolina, Verenigde Staten, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Verenigde Staten, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Verenigde Staten, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Verenigde Staten, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Verenigde Staten, 29672
        • Prisma Health Cancer Institute - Seneca
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Verenigde Staten, 23298
        • Virginia Commonwealth University/Massey Cancer Center
    • Wisconsin
      • La Crosse, Wisconsin, Verenigde Staten, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Verenigde Staten, 53215
        • Aurora Saint Luke's Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion.
  • Agrees to participate in all aspects of the intervention, randomization, and evaluation.
  • Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team.
  • Agrees to have the interview taped, transcribed and qualitatively analyzed.
  • Age ≥18 years
  • Potential participants will be screened using the following question: "Do you smoke cigarettes every day, some days, or not at all?" (BRFSS). A current smoker is anyone responds "every day" or "some days".

Exclusion Criteria:

  • Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement
  • Individuals who use e-cigarettes and who are not smoking cigarettes. Dual users (those who use both e-cigarettes and cigarettes) will still be included in the trial.
  • The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia).
  • Individual has already completed the intended LDCT lung cancer screening for this study.
  • Non-English speaking participants.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention

Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study

Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)

Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study

Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.

Geen tussenkomst: Usual Care

No training or performance coaching calls on personnel, just usual clinic practice.

Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey
Tijdsspanne: 6 months (after baseline)
7-day sustained smoking abstinence will be measured by the question "Have you smoked a cigarette (or other tobacco products), even a puff, in the last 7 days?" in patient survey.
6 months (after baseline)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Salivary Cotinine Test for Non-Smokers
Tijdsspanne: 6 months (after baseline)
7-day Sustained Smoking abstinence will be validated using a salivary cotinine test in non smokers. Abstinence will be determined by percentage of smokers whose tests come back negative for cotinine. Low levels of cotinine less than 15 milligrams per milliliter (mg/mL) would suggest true smoking cessation and levels higher than or equal to 15 mg/mL would suggest they are still smoking.
6 months (after baseline)
Short-term Smoking Abstinence - Patient Survey
Tijdsspanne: 3 months (after baseline)
Short-tem smoking abstinence will be measured as part of the patient survey as the percentage of patients who report that they have not smoked.
3 months (after baseline)
Total Number of Services Participant Reported Received at 14 Days
Tijdsspanne: <= 14 days after baseline
Fidelity to the intervention will be measured by a patient survey that asks patients if they received up to 18 cessation services during the screening visit. This is the total each participant reported receiving and can range from 0 to 18, with higher values representing more services.
<= 14 days after baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Kristie Foley, PhD, Wake Forest University Health Sciences

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 juni 2018

Primaire voltooiing (Werkelijk)

22 februari 2021

Studie voltooiing (Werkelijk)

22 februari 2021

Studieregistratiedata

Eerst ingediend

19 september 2017

Eerst ingediend dat voldeed aan de QC-criteria

19 september 2017

Eerst geplaatst (Werkelijk)

25 september 2017

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 juli 2022

Laatste update ingediend die voldeed aan QC-criteria

20 juli 2022

Laatst geverifieerd

1 juli 2022

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • IRB00040071
  • 1R01CA207158-01 (Subsidie/contract van de Amerikaanse NIH)
  • REBAWF-20817CD (Andere identificatie: NCI)
  • NCI-2017-01669 (Register-ID: NCI CTRP)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Wake Forest (WF) NCORP Research Base (RB) is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI National Clinical Trials Network (NCTN)/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials (https://nctn-data-archive.nci.nih.gov/). This will become the primary means for sharing raw data and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide.

IPD-tijdsbestek voor delen

see NIH policy

IPD-toegangscriteria voor delen

request using uniform resource locator (URL) below

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Stoppen met roken

Klinische onderzoeken op Personnel Training and Coaching Calls

Abonneren